AIM ImmunoTech Inc. Stock News

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

AIM ImmunoTech Inc (NYSE: AIM ) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic cancer patients. The study found that the median overall survival in the Ampligen group was 19 months, compared to a historical control group and subgroup (7.5 and 12.5, respectively). At six weeks, the Systemic Immune-Inflammation Index (SIII) and Neutrophils … Full story available on Benzinga.com

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AMERICAN ) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced today that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® (also known as rintatolimod) at the American Association for Cancer Research (AACR) Annual Meeting 2022 , being held April 8-13, 2022, in New Orleans, Louisiana. Research led by Roswell Park medical oncologists Shipra Gandhi, MD , and Sarbajit Mukherjee, MD, MS , in collaboration with senior investigator Pawel Kalinski, MD, PhD , Chair of Immunology at Roswell Park, has been accepted for presentation as late-breaking poster abstracts at … Full story available on Benzinga.

AIM ImmunoTech (AIM) said Ampligen following FOLFIRINOX, a chemotherapy combination, showed improved survival rates in patients with pancreatic cancer compared to matched controls…

Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX was…

Ampligen® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Eras

Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center

AIM ImmunoTech (AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M.The Company will retain access to space in…

OCALA, Fla., March 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therape

AIM ImmunoTech (AIM) has announced the appointment of Robert Dickey IV, as its Chief Financial Officer.Effective April 4, 2022, Mr

Industry veteran and financial and strategic leader with deep capital markets and business development transactional expertise across life science and medical device companies Industry veteran and fin

AIM ImmunoTech Inc (NYSE:AIM) has announced the appointment of Robert Dickey IV, as its chief financial officer (CFO).  Effective April 4, 2022, AIM ImmunoTech said, Dickey will become CFO and curr